<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02592720</url>
  </required_header>
  <id_info>
    <org_study_id>Cocktail II-FFR ACS</org_study_id>
    <nct_id>NCT02592720</nct_id>
  </id_info>
  <brief_title>Cocktail Injection Improves Outcomes of FFR Guided PCI</brief_title>
  <acronym>CocktailII</acronym>
  <official_title>Intracoronary Cocktail Injection Improves Outcomes of Fractional Flow Reserve Guided Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrom (ACS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, single blind, controlled study of intracoronary cocktail injection
      before fractional flow reserve (FFR) measurement when guiding percutaneous coronary
      intervention (PCI) in patients with acute coronary syndrome (ACS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, single blind, controlled study of intracoronary cocktail injection
      before fractional flow reserve (FFR) measurement when guiding percutaneous coronary
      intervention (PCI) in patients with acute coronary syndrome (ACS). Patients with ACS will be
      randomized into the cocktail plus FFR guided group or the QCA guided group. The primary
      outcome of the cocktail II study is the composite of death, myocardial infarction, class IV
      heart failure and target vessel revascularization within 1 year. The secondary outcome of the
      cocktail II study include left ventricular function, quality of life, stroke or
      life-threatening bleeding within 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiac events</measure>
    <time_frame>1 year</time_frame>
    <description>number of participants with death, myocardial infarction or class IV heart failure and target vessel revascularization revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>left ventricular function</measure>
    <time_frame>1 year</time_frame>
    <description>left ventricular ejection fraction evaluated by ultrasound and MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seattle Angina Questionnaire scores</measure>
    <time_frame>1 year</time_frame>
    <description>Seattle Angina Questionnaire scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Canadian Cardiovascular Society (CCS) Functional Angina classification</measure>
    <time_frame>1 year</time_frame>
    <description>Canadian Cardiovascular Society (CCS) Functional Angina classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minute walk distance (6MWD)</measure>
    <time_frame>1 year</time_frame>
    <description>6-minute walk distance (6MWD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stroke</measure>
    <time_frame>1 year</time_frame>
    <description>number of participants with stroke</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Acute Coronary Syndromes</condition>
  <arm_group>
    <arm_group_label>Cocktail plus FFR guided group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intracoronary cocktail injection before fractional flow reserve (FFR) measurement. Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QCA guided group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Percutaneous Coronary Intervention (PCI) strategy is decided by QCA value in patients with acute coronary syndrome (ACS).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cocktail</intervention_name>
    <description>Intracoronary cocktail injection before fractional flow reserve (FFR) measurement. Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).</description>
    <arm_group_label>Cocktail plus FFR guided group</arm_group_label>
    <other_name>cocktail (tirofiban, bivalirudin, tenecteplase)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FFR</intervention_name>
    <description>Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).</description>
    <arm_group_label>Cocktail plus FFR guided group</arm_group_label>
    <other_name>pressure wire (St. Jude Medical, Inc.)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>QCA guided group</intervention_name>
    <description>Percutaneous Coronary Intervention (PCI) strategy is decided by QCA value in patients with acute coronary syndrome (ACS).</description>
    <arm_group_label>QCA guided group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with a clinical diagnosis of recent ACS within 5 days

        Exclusion Criteria:

          -  haemodynamic instability

          -  intolerance to anti-platelet drugs

          -  ineligible for coronary revascularization

          -  a treatment plan for non-coronary heart surgery (e.g. valve surgery)

          -  a history of prior PCI or CABG

          -  angiographic evidence of severe (e.g. diffuse calcification) or mild (ï¼œ30% severity)
             coronary disease

          -  a life expectancy less than 1 year

          -  adenosine allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dongdong Sun, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fourth Military Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wanrong Man, MD</last_name>
    <phone>86 29 84775183</phone>
    <email>manwanrong@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dongdong Sun, MD,Phd</last_name>
    <phone>86 29 84775183</phone>
    <email>wintersun3@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xijing hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dongdong Sun, M.D.,Ph.D</last_name>
      <phone>86 18691569930</phone>
      <email>wintersun3@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2015</study_first_submitted>
  <study_first_submitted_qc>October 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2015</study_first_posted>
  <last_update_submitted>October 29, 2015</last_update_submitted>
  <last_update_submitted_qc>October 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xijing Hospital</investigator_affiliation>
    <investigator_full_name>sunddong</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Acute Coronary Syndromes</keyword>
  <keyword>Fractional Flow Reserve</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

